Charlie Morris Appointed to Almac’s Clinical Technologies Executive Team
News Dec 13, 2012
The Almac Group’s Clinical Technologies business unit has announced that Charlie Morris has joined the company as Vice President of New Products and Services.
In this role, Mr. Morris will report directly to Jim Murphy, President of Almac Clinical Technologies, and will oversee the development of Almac’s IXRS® technology and enhance the company’s metrics-based discipline to the software development process.
Mr. Morris brings extensive experience in systems management and development to Almac. His varied background includes service in the financial services, government, and medical technology sectors.
He has served in all stages of the systems development process, from inception to development to execution, and has significant experience managing international personnel.
Mr. Morris joins Almac after spending more than ten years serving as the Chief Technology Officer of Princeton Financial Systems (PFS), where he created and implemented multi-year IT strategic plans to grow and improve the PFS information technology infrastructure.
He led a team of technical staff in the development, integration, and continuous improvement of a suite of investment accounting, compliance, and data warehousing applications to support financial services industry clients.
Prior to his nearly two decades at PFS, Mr. Morris served as Director of Applications Development at Telescan Limited, building and implementing teleradiology systems.
He began his career in military contracts where he developed flight simulation, anti-submarine warfare, and naval intelligence systems.
Jim Murphy, President of Almac’s Clinical Technologies business unit, comments on Mr. Morris’ appointment: “We are thrilled that Charlie Morris has joined Almac. He will be instrumental to the continued development of our IXRS® integrated web and phone-based platform. Given his breadth of system development leadership experience, we are highly confident in his ability to align the New Products and Services department to support accelerated innovation of Almac’s technology. We welcome Charlie to Almac and know he will have a profound impact on the expansion of our technology offerings and client relationships.”
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
BC Platforms Announces Collaborations in Multiple Sclerosis ResearchNews
Company's technology and research platforms used to better understand genetic basis of MS.READ MORE
A New Tactic in the Fight Against Drug-Resistant InfectionsNews
$1 million research grant could lead to life-saving antibiotics.READ MORE